<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910808-0113</DOCNO><DOCID>910808-0113.</DOCID><HL>   Par Pharmaceutical's   Board Approves Shift   To Holding Company</HL><DATE>08/08/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B8</SO><CO>   PRX</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><GV>JUSTICE DEPARTMENT (JUS)</GV><RE>MARYLAND (MD)NORTH AMERICA (NME)NEW YORK (NY)UNITED STATES (US)</RE><LP>   SPRING VALLEY, N.Y. -- Par Pharmaceutical Inc. said itsboard approved a restructuring under which Par will become asubsidiary of a new holding company.   The company said the new structure won't change thebusiness or operations of Par, which will continue to makeand market its line of generic drugs. It said currentshareholders will automatically become holders of shares inthe new company, Pharmaceutical Resources Inc., next week,when the reorganization is expected to become effective.</LP><TEXT>   Par's chief executive officer, Kenneth I. Sawyer, said thenew holding company allows Par &quot;to acquire and dispose ofassets and attract potential investment with greaterflexibility.&quot; He said the company sees opportunities wherethe holding company/operating company structure would be&quot;advantageous.&quot;   A company spokesman noted that there are a number oflawsuits pending against Par, and that under the newstructure, the parent wouldn't be liable for prior acts ofthe subsidiary. He said the parent would be able to expandand seek financing, without risk from the lawsuits againstthe unit.   In January 1990, Par and its Quad Pharmaceuticals Inc.unit were fined for illegal payments made by two formerofficers to a Food and Drug Administration official, and Quadhas been barred from doing business with the federalgovernment until Aug. 31, 1992. The companies are underinvestigation by the U.S. attorney in Baltimore.   Par said it applied to list the common stock ofPharmaceutical Resources on the New York and Pacific stockexchanges, where Par common is currently listed.</TEXT></DOC>